A Phase 2 interventional study of AR-13324 Ophthalmic Solution 0.01% and AR-13324 Ophthalmic Solution 0.02% in Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-04-18.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 1st registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Brett King · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Center for Sight Las Vegas · Sites in United States
Ages 40+
By country, each count listing its studies:
netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2012.
This study's enrollment of 85 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 85 across the 17 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 80th largest by enrollment of the 112 interventional ones that give a count, is one of 9 that started in 2012, is one of 33 in phase 2, and was the 89th registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
2 of the studies testing netarsudil in Glaucoma, Open-Angle that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07048886Center for Sight Las VegasRocklatan Adds Pressure Reduction After MIGS (Minimally Invasive Glaucoma Surgery) | 2026-12-31 |
| NCT07325240Mayo Clinic24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, from their registry updates:
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
This study's enrollment of 85 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
First submitted before Aerie Pharmaceuticals became part of Alcon.
Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ophthalmic: Either eye
Central corneal thickness greater than 600 μm.
General/Systemic:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop to study eye once daily
Drug: AR-13324 Ophthalmic Solution 0.01%
1 drop to study eye once daily
Drug: AR-13324 Ophthalmic Solution 0.02%
1 drop to study eye once daily
Drug: AR-13324 Ophthalmic Solution 0.04%
1 drop to study eye once daily
Other: AR-13324 Ophthalmic Solution Vehicle
Administered to study eye, once daily (QD) in the morning (AM) for 7 days
Administered to study eye, QD AM for 7 days
Also known as: Netarsudil
Administered to study eye, QD AM for 7 days
Administered to study eye, QD AM for 7 days
Intraocular Pressure (IOP)
The primary efficacy outcome was the mean IOP across subjects within treatment group at each post-treatment timepoint of Day 8. Instillation of study treatment commenced on Day 2 following measurement of IOP. IOP was measured at 0800, 1000, 1200 and 1600 hours on days 2 and 8. IOP was also measured at 0800 hours on Day 4.
Time frame: Study treatment was administered for 7 days; starting on Day 2 and ending on Day 8.
| Milestone | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Opththalmic Solution Vehicle |
|---|---|---|---|---|
| Started | 22 | 21 | 19 | 23 |
| Completed | 22 | 21 | 18 | 22 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Family emergency | 0 | 0 | 1 | 0 |
The primary efficacy outcome was the mean IOP across subjects within treatment group at each post-treatment timepoint of Day 8. Instillation of study treatment commenced on Day 2 following measurement of IOP. IOP was measured at 0800, 1000, 1200 and 1600 hours on days 2 and 8. IOP was also measured at 0800 hours on Day 4.
| mmHg | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Ophthalmic Solution Vehicle |
|---|---|---|---|---|
| Day 2, 0800 hours | 25.80 ± 3.699 | 26.02 ± 2.542 | 26.50 ± 3.358 | 25.17 ± 2.980 |
| Day 2, 1000 hours | 22.45 ± 3.713 | 22.10 ± 3.149 | 24.29 ± 5.347 | 22.87 ± 2.681 |
| Day 2, 1200 hours | 21.93 ± 2.997 | 21.95 ± 3.653 | 25.00 ± 5.292 | 22.91 ± 2.863 |
| Day 2, 1600 hours | 20.70 ± 3.521 | 20.88 ± 3.467 | 22.29 ± 4.849 | 21.41 ± 3.110 |
| Day 4, 0800 hours | 21.32 ± 4.049 | 21.00 ± 4.530 | 22.00 ± 5.352 | 23.98 ± 3.730 |
| Day 8, 0800 hours | 20.82 ± 5.487 | 20.60 ± 3.491 | 20.44 ± 3.933 | 24.34 ± 3.663 |
| Day 8, 1000 hours | 18.20 ± 4.165 | 18.71 ± 3.208 | 19.42 ± 3.663 | 22.34 ± 4.034 |
| Day 8, 1200 hours | 17.57 ± 4.255 | 17.88 ± 3.457 | 18.78 ± 4.486 | 21.93 ± 3.818 |
| Day 8, 1600 hours | 17.68 ± 3.161 | 16.88 ± 3.049 | 17.83 ± 3.510 | 21.52 ± 4.244 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AR-13324 Ophthalmic Solution 0.01% | 0/22 (0%) | 0/22 (0%) | 12/22 (54.5%) |
| AR-13324 Ophthalmic Solution 0.02% | 0/21 (0%) | 0/21 (0%) | 15/21 (71.4%) |
| AR-13324 Ophthalmic Solution 0.04% | 0/19 (0%) | 0/19 (0%) | 17/19 (89.5%) |
| AR-13324 Ophthalmic Solution Vehicle | 0/23 (0%) | 0/23 (0%) | 1/23 (4.3%) |
| Event | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Ophthalmic Solution Vehicle |
|---|---|---|---|---|
| Conjunctival HyperaemiaEye disorders | 11/22 | 12/21 | 14/19 | 1/23 |
| Ocular HyperaemiaEye disorders | 1/22 | 1/21 | 3/19 | 0/23 |
| Instillation Site ReactionGeneral disorders | 0/22 | 0/21 | 2/19 | 0/23 |
| Vision BlurredEye disorders | 0/22 | 2/21 | 1/19 | 0/23 |
| Dry EyeEye disorders | 0/22 | 2/21 | 0/19 | 0/23 |
| Corneal StainingInvestigations | 0/22 | 2/21 | 1/19 | 0/23 |
| Erythema of EyelidEye disorders | 0/22 | 1/21 | 1/19 | 0/23 |
| DiplopiaEye disorders | 0/22 | 0/21 | 1/19 | 0/23 |
| Vitreous FloatersEye disorders | 0/22 | 0/21 | 1/19 | 0/23 |
| Blood Glucose IncreasedInvestigations | 0/22 | 1/21 | 1/19 | 0/23 |
| Age, Continuous(years) | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|---|
| Mean | 63.6 ± 12.36 | 69.1 ± 8.69 | 66.1 ± 11.09 | 57.8 ± 12.27 | 64.0 ± 11.83 |
| Sex: Female, Male(Participants) | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|---|
| Female | 14 | 14 | 10 | 13 | 51 |
| Male | 8 | 7 | 9 | 10 | 34 |
| Ethnicity (NIH/OMB)(Participants) | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 2 | 4 | 11 |
| Not Hispanic or Latino | 18 | 20 | 17 | 19 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | AR-13324 Ophthalmic Solution 0.01% | AR-13324 Ophthalmic Solution 0.02% | AR-13324 Ophthalmic Solution 0.04% | AR-13324 Ophthalmic Solution Vehicle | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 2 | 2 | 8 |
| White | 20 | 17 | 17 | 20 | 74 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
The record gives a start of Mar 2012, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 5 years 7 months after primary completion. A results delay was requested in Feb 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Netarsudil